LCMC3 evaluated neoadjuvant atezolizumab in pts w/resectable #NSCLC & reported a 20% major PathR rate. The dev of AI-powered approaches in clinical settings may aid pathologists in clinical operations to support improved pt care & long-term outcomes. bit.ly/4akxjos #LCSM

Become acquainted with the epidemiology, screening practices, and treatment options at the Sultanate of Brunei Darussalam in this month's Lung Cancer Worldwide article. Read Now: bit.ly/4bBWLHj Vijay Kumar Srinivasalu Anne-Marie Dingemans #LCSM

A carefully implemented LC screening program using LDCT leads to over 80% cure rates. This report identifies the key components of the program that allows for quality assurance and monitoring to allow for even further improvements in the future. bit.ly/47ZA5zg #LCSM

R0 resection & RT have been associated w/improved OS in patients w/TC. In the largest individual pt data set on patients w/TC reported to date, PORT was associated w/a meaningful OS benefit in pts w/advanced-stage TC after an R0 or R1/2 resection. bit.ly/4b9pVNJ #LCSM

In this retrospective analysis, the authors found no significant differences in Stage I lung cancers incidentally or screening detected with regard to tumor characteristics, surgical approach, and postoperative outcomes. bit.ly/3WeRl0q #LCSM Institute for Translational Epidemiology

Syria, a country wrought w/conflict for over a decade, has faced significant obstacles in their healthcare system for years. Read about the nation's current state of #lungcancer care in this month's Lung Cancer Worldwide article. bit.ly/3vXA4OJ Mousa Alali Maher Saifo

This paper represents a comprehensive review of evidence regarding R categories & the descriptors thereof. W/the same overall framework & descriptors in the 9th edition, refinements to the descriptors should facilitate application & further research.bit.ly/441RqX1 #IASLC

A study focused on whether STAS could be a useful add'l histologic descriptor to supplement existing ones of VPI & LVI. Data supports the recommendation to include STAS as a histologic descriptor for the 9th Edition of the TNM Classification of #lungcancer .bit.ly/3IZkx3x

Last Call! The last day to apply for the #IASLC #Reviewer Workshop is Monday, April 1. Join us at #WCLC24 for this one-day workshop for early and mid-career IASLC members. Open to members in the Americas. Apply Now at: iaslc.org/reviewer-works… #LCSM

Controversies in #LungCancer : Here are the reasons why some researchers and clinicians believe that the combination of chemotherapy and osimertinib should not be the first-line treatment for all advanced #EGFR + #NSCLC . bit.ly/4cAElI2 #LCSM

Controversies in #LungCancer : Read why some researchers and clinicians believe that the combination of chemotherapy and osimertinib should be the first-line treatment for all advanced #EGFR + #NSCLC . bit.ly/3vsDNU8 #LCSM

The authors describe the current landscape of pertinent clinical trials focusing on MET-targeted strategies and discuss future developmental directions in this rapidly expanding field. Read the review here: bit.ly/3IQFttt #LCSM

A first retrospective study to comprehensively characterize the genomic landscape of #NSCLC in Ireland, which has a higher prevalence of pts w/KRAS-mt NSCLC & a lower prevalence of ALK, ROS1 & RET fusion-positive NSCLC, compared w/similar data sets. bit.ly/3vrWU0w #LCSM

The Japanese prospective nationwide registry study on CIRT, which began in 2016, studied real-world clinical outcomes of CIRT for operable pts w/stage I #NSCLC . The authors found that this treatment method has favorable outcomes w/tolerable toxicity. bit.ly/4aqaNLk #LCSM

In the phase 3 RATIONALE-312 study, researchers evaluated efficacy & safety of tislelizumab + chemo as first-line treatment for ES-SCLC. This treatment demonstrated statistically significant clinical benefit & manageable safety compared to placebo + chemo. bit.ly/4akAXPN

The detection of tumor DNA in the supernatant of guide sheath flush fluid collected during r-EBUS bronchoscopy represents a sensitive & complementary method for genotyping #NSCLC , theoretically reducing the false-negative rate of DNA genotyping from plasma.bit.ly/3xcvrjO

The #Lung Cancer Worldwide series continues with Switzerland. Read more to learn the epidemiology, treatment, and the potential future of screening in Switzerland. bit.ly/3vaHsG8 #LCSM

Reminder! The last day to apply for the #IASLC #Reviewer Workshop is Monday, April 1. Join us at #WCLC24 for this one-day workshop for early and mid-career IASLC members. Open to members in the Americas. Apply at
iaslc.org/reviewer-works… JTO & JTO CRR #LCSM

This study analyzed all metastatic categories of the TNM classification of #NSCLC to propose modifications of the M component in the 9th edition, the data validates the 8th edition M1a & M1b categories. Read more including a proposal re: the M1c category: bit.ly/3IrQamc

To provide a more detailed analysis of TKIs' impact on pts w/EGFRmut #NSCLC , authors found that pts w/TP53mut/TSGmut tumors have an aggressive disease phenotype & inferior outcomes on EGFR TKIs, implying that some pts would benefit from add. therapy types. bit.ly/3Q6o8jr